Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Fulcrum Therapeutics, Inc. (FULC) had Stock-Based Compensation of $6.04M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-17.30M |
|
-- |
|
-- |
|
$19.82M |
|
$-19.82M |
|
$2.52M |
|
$-17.30M |
|
$-17.30M |
|
$-17.30M |
|
$-17.30M |
|
$-17.30M |
|
$-17.30M |
|
$-19.82M |
|
$-19.47M |
|
62.54M |
|
62.54M |
|
$-0.28 |
|
$-0.28 |
|
| Balance Sheet Financials | |
$219.37M |
|
$3.27M |
|
$9.46M |
|
$228.84M |
|
$8.98M |
|
-- |
|
$5.47M |
|
$14.46M |
|
$214.38M |
|
$214.38M |
|
$214.38M |
|
54.09M |
|
| Cash Flow Statement Financials | |
$-29.08M |
|
$13.16M |
|
$0.30M |
|
$59.41M |
|
$43.79M |
|
$-15.62M |
|
|
Stock-Based Compensation |
$6.04M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
24.42 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-29.14M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8.07% |
|
-8.07% |
|
-7.56% |
|
-8.07% |
|
$3.96 |
|
$-0.47 |
|
$-0.46 |
|